Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Sucker born every minute...
View:
Post by beechguy on Jun 03, 2014 9:43am

Sucker born every minute...

I haven't bought a share for over a year or so, but I pulled the trigger yesterday. With CEO COO and chairman buying, something must be going ok. One thing know about insiders; they don't like to part with hard earned money. When a ship is going down they are usually scurrying off the side. there is only one reason an insider buys... Cause a stock is perceived  to be undervalued by them.  We may still see .10 but any decent news on urocidin pathway or accelerated will likely send us over .50. 

I heard that Jennifer Shea has been let go, so the cost cutting continues. If only Graeme ha started cost cutting 5 years ago, we'd still own urocidin and AH. 

Beech
Comment by Tson99 on Jun 03, 2014 10:29am
Agreed Beech.  The new management is doing everything they said that they are going to do. If they continue to check off items on their list the market will begin to notice.  Also confirmed in the corporate update that they indeed did submit the clinical assessment package to Health Canada a full 1.5 months before the self-imposed deadline of June 30th. Under the old regime this would ...more  
Comment by Frogger2 on Jun 03, 2014 11:21am
In addition to your post Tson, I think that the recent submission would have more thorough and precise in regards to what HC requires as compared to previous management submissions. There is no reason to think they dealt with HC any different than they ran the business. We have been disappointed in the past but I feel very comfortable with Berendt in charge. Beech says .50 cents if we ...more  
Comment by NoNukNuk on Jun 03, 2014 11:56am
I'm not convinced yet.  There is still some mini-mansion building intended.   all of our expenditures are focussed on driving shareholder value through investment in the development and monetization of Urocidin™, our key Phase 3 bladder cancer program, and on building, through licensing and acquisition, a pipeline of differentiated human therapeutic products that will drive future ...more  
Comment by Frogger2 on Jun 03, 2014 2:01pm
Nuknuk, like it or not we started over six months ago with circumstances as they were then. We all know and are frustrated at what happened under former management, but that can't be changed. All we can do is look forward and make a decision for ourselves, either Berendt can get this done or he can't. The positive comments are directed towards a person who up to this point is  ...more  
Comment by NoNukNuk on Jun 03, 2014 5:14pm
I dunno Frogger.  The word acquistion sounds very similar to acquistion.  Maybe we need some clarification on this. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities